TRANSFUSION MEDICINE输血医学
TRANSFUSION MEDICINE(英文缩写 TRANSFUSION MED),ISSN 0958-7578,eISSN 1365-3148,中文译名:输血医学 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 2.057 | Q4 |
| 2022 | 1.500 | Q4 |
| 2023 | 1.500 | Q3 |
| 2024 | 1.400 | Q3 |
| 2025 | 1.300 | Q4 |
TRANSFUSION MEDICINE 最新收录文献
-
1. Improved blood component quality and processing efficiency with a fully automated whole blood preparation system.
PMID:日期:2026-09-29Automation in blood component preparation has emerged as a key strategy to improve standardisation, reduce operator-dependent variability, and enhance product quality and workflow efficiency. However, comparative real-world data between fully automated (FA) and semi-automated (SA) systems remain limited. In this retrospective study, a total of 699 blood component units, including 400 red blood cell concentrates (RCC), 199 pooled platelet concentrates (PPC), and 100 fresh frozen plasma (FFP) units prepared between June 2024 and June 2025, were analysed. Quality parameters such as volume, haemoglobin (Hb), total Hb content, haematocrit (Hct), hemolysis, potassium, platelet count, leukocyte count, pH, and Factor VIII activity were compared between FA and SA systems. Preparation times were also evaluated. The FA system significantly reduced preparation time for all blood components (p< 0.001). RCC units produced by FA demonstrated higher volume, weight, Hb, and Hct levels, along with lower haemolysis rates and potassium concentrations (p< .05). FA-prepared PPC units showed reduced leukocyte contamination and improved platelet yield, particularly in six-pool concentrates, while maintaining comparable pH values. In FFP analysis, erythrocyte counts, pH, and Factor VIII activity were similar between systems; however, FA units exhibited significantly lower leukocyte levels, whereas SA units had higher volume and weight (p< 0.05). Fully automated whole blood preparation systems significantly enhance operational efficiency and improve key quality parameters of blood components compared with semi-automated methods. The adoption of automation may contribute to improved transfusion safety, better resource utilisation, and greater standardisation in blood component preparation.
-
2. Preoperative intravenous iron and red blood cell transfusion requirements in elderly intertrochanteric femoral fractures.
PMID:日期:2026-09-24Intravenous (IV) iron is used in patient blood management for elderly patients with hip fractures, but its effectiveness in reducing red blood cell (RBC) transfusion remains unclear. This study evaluated the effect of preoperative IV iron on perioperative RBC transfusion volume and identified associated factors. We retrospectively reviewed 307 patients aged ≥65 years who underwent cephalomedullary nailing for intertrochanteric femoral fractures between 2018 and 2021. From November 2020, patients routinely received preoperative IV iron; earlier patients did not (180 non-IV iron and 127 IV iron). Patient, fracture, surgical and transfusion variables were compared. Multiple regression identified factors associated with total perioperative transfusion volume. Total perioperative RBC transfusion volume did not differ between the non-IV iron and IV iron groups (292.1 vs. 272.7 mL, p = 0.868). In multiple regression analysis, significant predictors were AO Foundation/Orthopaedic Trauma Association fracture classification (β = 73.1 mL, 95% confidence interval [CI] 32.4-113.7, p < 0.001), spinal anaesthesia (β = -78.9 mL, 95% CI -144.3 to -13.5, p = 0.018), operative time (β = 2.9 mL/min, 95% CI 0.5-5.2, p = 0.020) and admission haemoglobin level (β = -94.6 mL/g/dL, 95% CI -111.1 to -78.1, p < 0.001). Preoperative IV iron was not independently associated with transfusion volume (β = -49.7 mL, 95% CI -103.1 to 3.7, p = 0.068). Preoperative IV iron did not significantly reduce perioperative RBC transfusion requirements in elderly patients with intertrochanteric femoral fractures. Shorter operative time and spinal anaesthesia were associated with lower transfusion volume.
-
3. Developing key performance indicators using routinely collected healthcare data in obstetric patient blood management: A multi-stage consensus study.
PMID:日期:2026-09-11Patient blood management (PBM) including appropriate red blood cell (RBC) transfusion underpins the management of severe anaemia and haemorrhage during pregnancy, delivery and postpartum. However, there is marked variation in practice despite guidelines and standards. Key performance indicators (KPIs) can identify deviation from agreed standards, support benchmarking and guide efforts to improve outcomes. We aimed to develop a set of obstetric PBM KPIs which may be measured from routinely collected electronic health records. We undertook a three-stage process. First, we completed a scoping review to identify potential KPIs from relevant literature and clinical guidelines. Second, we conducted a modified RAND consensus process with a multidisciplinary panel of medical professionals. The consensus panel rated potential KPIs according to importance and feasibility. Third, our research team undertook a 'sense check' to refine and make the final selection of the KPIs. Out of 25 candidate KPIs initially identified, we derived a final set of 10 KPIs covering PBM in obstetrics and the RBC transfusion practice. Fifteen candidate KPIs were rejected: 6 KPIs were judged neither important nor feasible, 2 not feasible for further study at the current time, 2 not important to the general obstetric population and 5 represented organisation of care, rather than clinical practice. Using a systematic, stepwise, transparent approach, we have developed a set of 10 KPIs based on routine health data sources to monitor and guide improvement of PBM implementation, particularly RBC transfusion practice in obstetrics. These KPIs now require further field testing using routinely collected data.
-
4. Red blood cell-directed immune responses in COVID-19: Mechanisms, clinical evidence and implications for transfusion medicine.
PMID:日期:2026-09-06SARS-CoV-2 infection is associated with a broad spectrum of red blood cell (RBC)-directed immune responses, ranging from isolated direct antiglobulin test (DAT) positivity to autoimmune hemolytic anemia (AIHA) and transfusion-related diagnostic challenges. This narrative review integrates current evidence on the mechanisms underlying these abnormalities, their clinical manifestations, and their implications for transfusion medicine. Molecular mimicry, bystander B-cell activation, complement dysregulation, oxidative membrane injury, and structural erythrocyte remodeling appear to represent interconnected mechanisms promoting immune recognition and altered function of RBCs. DAT positivity is frequently observed in hospitalized patients with COVID-19, often in the absence of clinically significant hemolysis, emphasizing that a positive DAT should not be considered synonymous with AIHA. Autoantibodies, complement deposition, and occasional alloimmune responses may complicate antibody identification, compatibility testing, and selection of appropriate blood components. Available evidence remains limited by heterogeneous study designs and the predominance of observational studies and case reports. Recognition of RBC-directed immune responses as part of COVID-19-associated immune dysregulation may improve interpretation of immunohematological findings, facilitate appropriate transfusion support, and help distinguish clinically significant immune hemolysis from isolated serological abnormalities.
-
5. Managing pregnancy in women with the Rh-null phenotype: A structured narrative review of alloimmunisation, maternal-fetal outcomes and transfusion management.
PMID:日期:2026-09-04The Rh-null phenotype is the rarest known red blood cell phenotype and is characterised by the complete absence of Rh antigens. During pregnancy, women with the Rh-null phenotype face unique challenges related to alloimmunisation against high-prevalence Rh antigens, haemolytic disease of the fetus and newborn, and the extremely limited availability of compatible blood for maternal or neonatal transfusion. We conducted a structured narrative review to identify published reports describing pregnancy-related or neonatal outcomes associated with the Rh-null phenotype, focusing on maternal antibody status, transfusion management, fetal monitoring, intrauterine intervention and maternal and neonatal outcomes. Eight reports published between 1983 and 2024 were identified. Anti-Rh29 was explicitly reported in three cases, whereas additional reports described panreactive antibody patterns consistent with antibodies directed against high-prevalence Rh antigens. Clinical outcomes ranged from mild neonatal haemolysis to severe fetal or neonatal disease. One pregnancy required intrauterine transfusion for severe fetal anaemia, and another neonate underwent repeated exchange transfusions because of severe haemolytic disease. Antenatal autologous blood donation was reported in one case as a proactive transfusion strategy. Pregnancy in women with the Rh-null phenotype requires advanced immunohaematologic investigation and specialised transfusion support. Early identification of Rh-null status, comprehensive antibody evaluation, coordinated maternal-fetal surveillance and proactive transfusion planning are central to management, ideally through multidisciplinary collaboration and access to rare donor resources.
-
6. Not all anti-CD38 antibodies are created equal: The epitope of felzartamab is partially DTT-resistant.
PMID:日期:2026-09-02To evaluate anti-CD38 antibody candidates for their ability to bind to DTT-treated CD38 and red blood cells (RBCs). Dithiothreitol (DTT) treatment of RBCs is routinely used to denature CD38 and mitigate interference from anti-CD38 antibodies, such as daratumumab and isatuximab, in immunohematology testing. However, new anti-CD38 antibodies are in development, some of which may be directed against linear or otherwise DTT-resistant epitopes. Anti-CD38 antibody candidates were titrated in an enzyme-linked immunosorbent assay (ELISA) to assess their ability to bind to untreated and DTT-treated recombinant CD38. Antibody binding was subsequently confirmed by flow cytometry of RBCs. Daratumumab and felzartamab were then tested on a panel of native and DTT-treated RBCs in the indirect antiglobulin test (IAT). All antibodies except felzartamab failed to bind to DTT-denatured CD38 in ELISA at concentrations up to 1.25 μg/mL. Flow cytometry confirmed this binding pattern. In the IAT, some DTT-treated cells remained positive with felzartamab, despite being negative with daratumumab. Not all epitopes of anti-CD38 antibodies are fully DTT-sensitive. This has important implications for handling of anti-CD38 antibody induced interference in immunohematology, and raises the question of whether DTT is an adequate solution for interference mitigation.
-
9. From prediction to practice: Barriers to implementing artificial intelligence in blood inventory management and transfusion support.
PMID:日期:2026-08-04Artificial intelligence (AI) is increasingly applied to blood-demand forecasting, donor management, inventory optimisation, wastage reduction and transfusion-related decision support; however, routine implementation remains limited. To review current applications of AI in blood inventory management and transfusion support and identify the principal barriers to safe and sustainable implementation. A focused narrative review informed by structured searches of PubMed, Scopus, EBSCO and Google Scholar, supplemented by targeted searches of transfusion-specific and healthcare AI implementation literature. Evidence was synthesised thematically. Published studies demonstrate technical feasibility across forecasting, donor-return prediction, inventory management and clinical decision support. Major implementation barriers include limited external and prospective validation, incomplete reporting, data-access and privacy constraints, poor interoperability, limited explainability, workforce training gaps and unclear governance. The principal challenge is no longer developing predictive models but integrating them safely and sustainably into routine transfusion services. Future progress requires multicentre evaluation, privacy-preserving data collaboration, workflow-integrated design, role-specific training and explicit governance with continued human oversight.
-
10. Seroprevalence of hepatitis B and C in asymptomatic blood donors in Saudi Arabia: A systematic review and meta-analysis.
PMID:日期:2026-07-31Viral hepatitis remains a serious risk to transfusion safety, despite being considerably reduced by donor screening. Objectives: The aim of this study was to evaluate the seroprevalence of HBV and HCV among asymptomatic blood donors in Saudi Arabia in the past 15 years (2010-2025). A literature search has been conducted on seven databases. Prevalence rates with 95% confidence intervals (CIs) were pooled via a random effects model. Twelve studies, examining 597 820 blood donors, were included in this study. The overall pooled prevalence rate of HBV and HCV among blood donors was 0.455% (95% CI: 0.334%-0.619%) and 0.195% (95% CI: 0.130%-0.292%), respectively. Although a high heterogeneity was detected across studies (I >80%, p = 0.000), sensitivity analysis revealed strong reliability, and no publication bias was detected. Subgroups and meta-regression analyses demonstrated that publication period, geographic location, and diagnostic methods were the main factors contributing to heterogeneity in prevalence estimates for HBV and HCV. According to our findings, the prevalence of positive blood donors for HBV and HCV is low across Saudi Arabia. We suggest that vaccination campaigns and public education regarding the modes of transmission should be improved in order to reduce the prevalence of blood-borne viruses.